Bioxyne (ASX:BXN) has announced that its wholly-owned subsidiary, Breathe Life Sciences (BLS), has signed an amendment to its existing manufacturing and supply agreement with Aura Therapeutics.
Aura Therapeutics is an Australian medicinal cannabis distributor.
Bioxyne said the amendment expands the scope of the original agreement to include the manufacture of edible cannabis pastilles and doubles the forecast volumes of cannabis flower products.
Based on the forecast volumes signed off by Aura Therapeutics, BLS is expected to generate up to $5.94 million in annual sales. Of this, $3.14 million is expected from pastille production and $2.80 million from cannabis flower products.
All products will be manufactured under BLS’s Good Manufacturing Practice licence, which the TGA grants.
Bioxyne managing director and Breathe Life Sciences founder and CEO Sam Watson said, “As a leading Australian cannabis manufacturer, we are supplying Australian-made pharmaceutical goods to both domestic and international markets. We are proud to be the trusted manufacturing partner of great companies like the one Tom Fay and his associates have built.”